 |
市場調査レポート
商品コード
721692
ウェアラブルインジェクターの世界市場の予測 ～2023年：オンボディ型・オフボディ型 (輸液ポンプ型)Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson's disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023 |
||||||
| ウェアラブルインジェクターの世界市場の予測 ～2023年：オンボディ型・オフボディ型 (輸液ポンプ型) |
|
出版日: 2018年10月08日
発行: MarketsandMarkets
ページ情報: 英文 105 Pages
納期: 即納可能
 |
世界のウェアラブルインジェクターの市場は予測期間中11.1%のCAGR (年間複合成長率) で推移し、2018年の55億7000万米ドルから、2023年には94億1000万米ドルの規模に成長すると予測されています。対象疾患の有病率の拡大、良好な償還環境、技術的進歩などの要因が同市場の成長を推進する見通しです。
当レポートでは、世界のウェアラブルインジェクターの市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、タイプ・治療区分・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。
The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from an estimated USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. The growing prevalence of targeted therapies, favorable reimbursement, and technological advancements in wearable injectors are expected to drive the growth of the wearable injectors market. However, the preference for alternative routes of drug delivery such as pens & autoinjectors is expected to restrain the growth of this market to a certain extent.
Based on type, the market is segmented into on-body and off-body injectors. The off-body injectors segment is expected to register the highest CAGR during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased demand for off-body injectors.
Based on therapy, the global wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson's disease, thalassemia, and primary immunodeficiency disorders). The cardiovascular diseases segment is expected to witness the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high burden of CVDs across the globe coupled with the growing availability of wearable injectors for the treatment of CVDs.
North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the US and Canada.
Breakup of primary participants is mentioned below:
The key players in the global wearable injectors market are: Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), Valeritas (US), SteadyMed Therapeutics (US), Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).
The report analyzes the wearable injectors market and aims at estimating the market size and future growth potential of this market based on various segments such as type, therapy, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.
This report provides insights on the following pointers:
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
比較リスト
